Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 9, 2025, the Board of Directors (the "Board") of Predictive Oncology Inc. (the "Company"), upon the recommendation of the Compensation Committee of the Board, determined that it was appropriate to award restricted stock units ("RSUs") as a form of compensation for employees, consultants and directors, to be granted under the Company's 2024 Equity Incentive Plan. In connection therewith, the Board approved a form of Restricted Stock Unit Award Agreement.

Consistent with the above determination, on September 9, 2025, upon the recommendation of the Compensation Committee, the Board approved the grant of 124,959 RSUs to Raymond F. Vennare, the Company's Chief Executive Officer and 97,000 RSUs to Josh Blacher, the Company's Interim Chief Financial Officer. Each RSU represents the right to receive one share of the Company's common stock upon vesting. The RSUs will vest in full on October 31, 2025, subject to continued service through the vesting date.

The form of Restricted Stock Unit Award Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K. The foregoing description of the RSU grants to Messrs. Vennare and Blacher is qualified in its entirety by reference to the complete terms and conditions of the form of Restricted Stock Unit Award Agreement, incorporated herein by reference.